SCHEMBL4629385

SCHEMBL4629385

Cc1ccccc1C(=O)NC(=N)Nc1ccc(C(C)C)cc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.51
HPGD P15428 1/20 0.51
KMT2A Q03164 2/20 0.50
ALDH1A1 P00352 5/20 0.48
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
MAPT P10636 2/20 0.47
ALOX12 P18054 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
TYK2 P29597 1/20 0.47
FFAR1 O14842 2/20 0.46
THRB P10828 2/20 0.46
CRHBP P24387 1/20 0.46
CRHR2 Q13324 1/20 0.46
LMNA P02545 1/20 0.45
TRPV1 Q8NER1 1/20 0.44
MEN1 O00255 1/20 0.44
GAA P10253 1/20 0.44
DHODH Q02127 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4627470 0.86 ALDH1A1 (0.51) SMN1; SMN2KMT2AALDH1A1NPC1RAB9A
SCHEMBL17660206 0.86 HPGD (0.70) SMN1; SMN2HPGDKMT2AALDH1A1NPC1
SCHEMBL4627435 0.84 NPC1 (0.56) SMN1; SMN2KMT2AALDH1A1NPC1RAB9A
SCHEMBL4629403 0.82 CRHBP (0.52) SMN1; SMN2HPGDKMT2AALDH1A1NPC1
SCHEMBL4629439 0.82 JAK2 (0.49) SMN1; SMN2HPGDKMT2AALDH1A1NPC1
SCHEMBL2503451 0.79 HPGD (0.56) SMN1; SMN2HPGDKMT2AALDH1A1NPC1
SCHEMBL4628708 0.78 ALDH1A1 (0.48) HPGDKMT2AALDH1A1NPC1RAB9A
SCHEMBL4628446 0.78 SCN5A (0.54) SMN1; SMN2KMT2AALDH1A1NPC1RAB9A
SCHEMBL4629293 0.77 ALDH1A1 (0.47) SMN1; SMN2HPGDKMT2AALDH1A1NPC1
SCHEMBL4628729 0.76 TAS1R3 (0.49) SMN1; SMN2HPGDKMT2AALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1032556-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE WYETH CORP (US) 2007-12-19 EP claimed
US-7041702-B1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-05-09 US claimed
EP-1918272-A1 Pharmaceutically active compounds and methods of use Wyeth a Corporation of the State of Delaware (US) 2008-05-07 EP disclosed
EP-1032556-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE WYETH CORP (US) 2007-12-19 EP disclosed
US-20060270741-A1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-11-30 US disclosed
US-7041702-B1 Pharmaceutically active compounds and methods of use SCION PHARMACEUTICALS, INC. (US) 2006-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270741-A1 Pharmaceutically active compounds and methods of use GBA1, CTSA, GAA SMN1; SMN2 53/4885HPGD 356/4885KMT2A 3245/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.